Zhong et al. discovered that diosgenin mitigated mitochondrial fission–fusion barriers by inhibiting DNM1L and increasing MFN 1/MFN 2 expression, thereby enhancing fatty acid oxidation and mitochondrial function in type 2 diabetes-related MASLD [41]. This evidence concerns the gene DNM1L and metabolic dysfunction-associated steatotic liver disease.